- Investing Ideas
- /
- Danish Pharmaceuticals & Biotech High Growth Potential Companies
Danish Pharmaceuticals & Biotech High Growth Potential Companies
Results
6
Companies with a Future performance score of at least 3, ordered by Future performance score.
6 companies
Gubra
Market Cap: DKK 6.4b
A biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.
GUBRA
DKK 389.60
7D
1.4%
1Y
18.8%
Novo Nordisk
Market Cap: DKK 2.0t
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
NOVO B
DKK 453.65
7D
2.4%
1Y
-51.1%
ChemoMetec
Market Cap: DKK 9.2b
Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally.
CHEMM
DKK 528.00
7D
3.7%
1Y
45.4%
Genmab
Market Cap: DKK 85.0b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 1,379.50
7D
1.4%
1Y
-28.8%
Zealand Pharma
Market Cap: DKK 32.1b
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.
ZEAL
DKK 453.50
7D
10.9%
1Y
-29.1%
ALK-Abelló
Market Cap: DKK 39.3b
Operates as an allergy solutions company in Europe, North America, and internationally.
ALK B
DKK 177.90
7D
2.5%
1Y
16.6%